CN120324576A - 腹水的治疗 - Google Patents

腹水的治疗

Info

Publication number
CN120324576A
CN120324576A CN202510468211.6A CN202510468211A CN120324576A CN 120324576 A CN120324576 A CN 120324576A CN 202510468211 A CN202510468211 A CN 202510468211A CN 120324576 A CN120324576 A CN 120324576A
Authority
CN
China
Prior art keywords
terlipressin
ascites
continuous infusion
patient
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510468211.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·昂厄利
P·马卡姆
J·阿达姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovie Inc
Original Assignee
Nanoantibiotics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57609113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN120324576(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nanoantibiotics Inc filed Critical Nanoantibiotics Inc
Publication of CN120324576A publication Critical patent/CN120324576A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
CN202510468211.6A 2015-06-30 2016-06-30 腹水的治疗 Pending CN120324576A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562186638P 2015-06-30 2015-06-30
US62/186,638 2015-06-30
US201562267510P 2015-12-15 2015-12-15
US62/267,510 2015-12-15
US201662321558P 2016-04-12 2016-04-12
US62/321,558 2016-04-12
PCT/US2016/040284 WO2017004317A1 (en) 2015-06-30 2016-06-30 Treatment of ascites
CN201680003239.1A CN106999539A (zh) 2015-06-30 2016-06-30 腹水的治疗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680003239.1A Division CN106999539A (zh) 2015-06-30 2016-06-30 腹水的治疗

Publications (1)

Publication Number Publication Date
CN120324576A true CN120324576A (zh) 2025-07-18

Family

ID=57609113

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510468211.6A Pending CN120324576A (zh) 2015-06-30 2016-06-30 腹水的治疗
CN201680003239.1A Pending CN106999539A (zh) 2015-06-30 2016-06-30 腹水的治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680003239.1A Pending CN106999539A (zh) 2015-06-30 2016-06-30 腹水的治疗

Country Status (7)

Country Link
US (6) US9655945B2 (https=)
EP (2) EP3347032B1 (https=)
JP (6) JP2017014206A (https=)
CN (2) CN120324576A (https=)
ES (1) ES2971959T3 (https=)
HK (1) HK1258611A1 (https=)
WO (1) WO2017004317A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101814186B1 (ko) 2008-09-17 2018-03-14 키아스마 인코포레이티드 약제학적 조성물 및 연관된 투여방법
US10335452B2 (en) 2014-10-24 2019-07-02 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
IL313083A (en) 2016-10-21 2024-07-01 Amryt Endo Inc Terlipressin compositions and their methods of use
CN112704727B (zh) * 2021-01-12 2023-05-16 重庆医科大学附属第二医院 特利加压素在制备动力性肠梗阻药物中的应用
CN113077888A (zh) * 2021-03-30 2021-07-06 福州宜星大数据产业投资有限公司 自动化meld评分方法、终端及存储介质
JP2025505010A (ja) * 2022-02-03 2025-02-19 バイオビー インコーポレーテッド テルリプレシンを用いた疾患の治療方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188443A1 (en) * 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
DK1984012T3 (en) * 2006-02-13 2016-03-29 Ferring Bv USE OF peptidic vasopressin receptor agonists
WO2009037586A2 (en) * 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
EP2203172A2 (en) * 2007-09-28 2010-07-07 Ferring B.V. Use of v2 receptor antagonists in combination with vasopressinergic agonists
WO2009062174A1 (en) * 2007-11-08 2009-05-14 University Of Utah Research Foundation Use of angiogenesis antagonists in conditions of abnormal venous proliferation
US8815232B2 (en) * 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
CN102369296A (zh) * 2009-03-09 2012-03-07 生物蛋白有限公司 Mirac蛋白
CN104434894A (zh) * 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
KR20130026504A (ko) * 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
WO2013106072A1 (en) 2012-01-10 2013-07-18 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation-binding polymers and uses thereof
JO3109B1 (ar) * 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
CN102731625B (zh) * 2012-06-27 2014-10-15 深圳翰宇药业股份有限公司 一种纯化特利加压素的方法
CA2891281C (en) * 2012-11-12 2023-11-28 The Regents Of The University Of Colorado, A Body Corporate Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
EP2988770A4 (en) * 2013-04-26 2016-12-14 La Jolla Pharma Co COMPOSITIONS AND METHOD FOR TREATING KIDNEY FAILURES
US20150056194A1 (en) * 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Modified green tea polyphenols and methods thereof for treating liver disease
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Also Published As

Publication number Publication date
EP3347032B1 (en) 2023-11-29
US20240165193A1 (en) 2024-05-23
EP3347032A4 (en) 2019-06-19
JP2020172520A (ja) 2020-10-22
JP2022136104A (ja) 2022-09-15
ES2971959T3 (es) 2024-06-10
WO2017004317A1 (en) 2017-01-05
US20190365848A1 (en) 2019-12-05
HK1258611A1 (zh) 2019-11-15
JP2025143324A (ja) 2025-10-01
US20170000844A1 (en) 2017-01-05
US9655945B2 (en) 2017-05-23
US11364277B2 (en) 2022-06-21
CN106999539A (zh) 2017-08-01
EP4338795A2 (en) 2024-03-20
JP2023160839A (ja) 2023-11-02
US20230146264A1 (en) 2023-05-11
JP2017014206A (ja) 2017-01-19
US20180000887A1 (en) 2018-01-04
EP4338795A3 (en) 2024-08-28
US20250312410A1 (en) 2025-10-09
EP3347032A1 (en) 2018-07-18
JP2018172440A (ja) 2018-11-08

Similar Documents

Publication Publication Date Title
CN120324576A (zh) 腹水的治疗
Chauhan et al. Emphysematous pyelonephritis (class IIIa) managed with antibiotics alone
JP7760169B2 (ja) 腎機能改善用組成物
CN104434788A (zh) 一种阿替洛尔注射液的制备方法
Lau et al. Continuous IV Deferoxamine for Chronic Iron Overload in Patients Undergoing Hemodialysis by Home Parenteral Therapy: A Case Report and Literature Review
Zhao A Case Analysis of Antihypertensive Treatment in a Patient Undergoing CRRT with Comorbid Coronary Heart Disease
CN1064234C (zh) 二咖啡酰氧基--奎宁酸在制药中的应用
Riaz et al. Drug-Induced Fanconi Syndrome Presenting as Chronic Constipation: A Well-Known but Forgotten Entity: PUB196
Dweik et al. Unsettling Lactate Levels: A Hint Toward Metformin Toxicity: PUB198
Mckellar et al. Hyperkalaemia: causes, electrocardiographic changes and management
Sheikh et al. Iron Poisoning and the Utility of Continuous Renal Replacement Therapy (CRRT): SA-PO605
Pintado et al. Dialysis Disequilibrium Syndrome in a Patient with a Relatively Low Blood Urea Nitrogen (BUN): SA-PO608
Kaur et al. Ifosfamide-Induced Neurotoxicity Treated with CRRT: SA-PO606
Imai et al. Is calcium replacement therapy unnecessary for severe hypocalcemia associated with rhabdomyolysis?
Hofkens et al. Metformin-associated lactic acidosis (MALA): case report
WO2016139740A1 (ja) 肝線維化改善剤
CN102872115A (zh) Houttuynoid A在治疗急性肾衰药物中的应用
CN119745845A (zh) 小分子n-甲基十二烷基胺在制备防治慢性肾病和高尿酸血症药物中的应用
Priyankara Two lesser known causes of hyperkalaemia
CN102861008A (zh) Aphanamixoid A在治疗急性肾衰药物中的应用
Kang Lactic acidosis and medication reconciliation error: case report
Dumbarton et al. Prolonged methylene blue infusion in refractory septic shock: a case report Perfusion prolongée de bleu de méthylene dans un cas de choc septique réfractaire: une présentation de cas
Hurley After SCI, Short Sleep Duration Raises Stroke Risk
Sukesan Various drugs Hyperkalaemia leading to heart arrest?: case
Bridwell EM@ 3AM: Peritoneal Dialysis Emergencies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination